v3.25.4
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Operating expenses:    
Research and development $ 3,046,448 $ 3,471,671
General and administrative 3,906,524 3,689,648
Sales and marketing 8,297
Total operating expenses 6,952,972 7,169,616
Operating loss (6,952,972) (7,169,616)
Other income (expense):    
Interest expense (839) (823,028)
Interest income 97,559 145,823
Other income, net 7,769 129,027
Total other income (expense), net 104,489 (548,178)
Net loss (6,848,483) (7,717,794)
Deemed dividend on warrant modification 13,223,053
Net loss applicable to common stockholders $ (6,848,483) $ (20,940,847)
Net Loss per share to common stockholders – Basic (in Dollars per share) $ (15.25) $ (456.75)
Net Loss per share to common stockholders – Diluted (in Dollars per share) $ (15.25) $ (456.75)
Weighted average common shares outstanding:    
Weighted average common shares outstanding – Basic (in Shares) 449,043 45,848
Weighted average common shares outstanding – Diluted (in Shares) 449,043 45,848